DBV Technologies (NASDAQ:DBVT) Sees Strong Trading Volume – Here’s Why

DBV Technologies S.A. (NASDAQ:DBVT) saw unusually-strong trading volume on Tuesday . Approximately 341,260 shares changed hands during trading, an increase of 15% from the previous session’s volume of 295,852 shares.The stock last traded at $14.06 and had previously closed at $14.57.

Analysts Set New Price Targets

Several research analysts recently issued reports on DBVT shares. Citigroup restated an “outperform” rating on shares of DBV Technologies in a research report on Friday, May 1st. Citizens Jmp lifted their price target on shares of DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Tuesday, June 30th. HC Wainwright reaffirmed a “buy” rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Weiss Ratings cut shares of DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 17th. Finally, Wall Street Zen downgraded shares of DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $48.50.

DBV Technologies Price Performance

The stock’s fifty day simple moving average is $16.79 and its two-hundred day simple moving average is $19.37. The company has a market capitalization of $807.03 million, a price-to-earnings ratio of -3.88 and a beta of -0.95.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings results on Thursday, July 16th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.48). The company had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.90 million. DBV Technologies had a negative return on equity of 119.33% and a negative net margin of 3,506.53%. On average, sell-side analysts predict that DBV Technologies S.A. will post -2.05 EPS for the current year.

Hedge Funds Weigh In On DBV Technologies

Several hedge funds and other institutional investors have recently modified their holdings of the company. GAMMA Investing LLC boosted its stake in DBV Technologies by 38.4% during the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after purchasing an additional 744 shares during the period. Truvestments Capital LLC increased its stake in shares of DBV Technologies by 71.3% in the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after purchasing an additional 1,620 shares during the period. Allworth Financial LP bought a new stake in shares of DBV Technologies during the fourth quarter valued at approximately $32,000. Royal Bank of Canada bought a new stake in shares of DBV Technologies during the fourth quarter valued at approximately $34,000. Finally, Persistent Asset Partners Ltd acquired a new stake in DBV Technologies in the 4th quarter valued at approximately $115,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.